Idenix Pharmaceuticals (IDIX) Initiates Proof-of-Concept Study of IDX184 for the Treatment of Hepatitis C Virus (HCV)
More News related to IDIX
- Thomas Weisel Initiates Coverage on Idenix Pharmaceuticals (IDIX) with an Overweight
- Goldman Sachs Downgrades Idenix Pharmaceuticals (IDIX) to Sell
- SmithKline Beecham to Resale 2.475M Shares of Idenix Pharma (IDIX)
- Idenix Pharmaceuticals to Present at The Deutsche Bank 2009 Health Care Conference
- Idenix Pharma (IDIX) Reports Better-Than Expected Q4 Loss of $0.25
Idenix Pharmaceuticals, Inc. (Nasdaq: IDIX) announced that it has initiated a proof-of-concept study of IDX184, a liver-targeted nucleotide prodrug candidate for the treatment of HCV under an Investigational New Drug application (IND) with the U.S. Food and Drug Administration (FDA). The study is evaluating IDX184 in treatment-naive hepatitis C genotype-1 infected patients.
"We are very pleased with the progress that we have made in our hepatitis C discovery program in 2008, having successfully advanced IDX184 from IND to a proof-of-concept study, while simultaneously advancing two additional HCV discovery programs into IND-enabling preclinical studies," said Jean-Pierre Sommadossi, Ph.D., chief executive officer of Idenix. "As we work to finalize a partnership for our lead HIV drug candidate, our goal in 2009 is to become the first biopharmaceutical company with innovative drugs from three major classes of direct-acting hepatitis C antivirals in clinical development."
Subscribe to EasyStockAlerts.com & Get real-time e-mail alerts when news hits your stocks!
Idenix Pharmaceuticals, Inc., is a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral and other infectious diseases.
Related Categories
Corporate NewsFDA
Stocks Mentioned
-0.21Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
